-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|March 14, 2025

How Bispecific Antibodies Are Reshaping Cancer Care

Experts discuss how the availability of bispecific therapies has influenced treatment paradigms in oncology and how bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors.

Video content above is prompted by the following:

  • How has the availability of bispecific therapies influenced treatment paradigms in oncology?
  • How do bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors?

Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.